This quarter's round-up of cutting-edge cancer research includes a way to fight chemo brain, controlling cancer cell death, and...
“The immuno-oncology revolution is now about 15 years into clinical reality,” said Carl June, MD, FAACR, director of the...
As we move slowly toward longer days and warmer temperatures, we bring you the latest round of highlighted articles...
Seven immune checkpoint inhibitors, targeting the PD-1, PD-L1, or CTLA-4 proteins, are currently approved for the treatment of cancer....
The year 2021 defied our expectations in a variety of ways. The delta and omicron COVID-19 variants imposed unprecedented...
We’re closing out 2021 on the blog with Editors’ Picks, our monthly staple featuring articles handpicked by the editors of the AACR...
On December 23, 1971, when President Richard Nixon signed the National Cancer Act of 1971 into law, cancer was considered a death sentence. Only 42 percent of those diagnosed with cancer survived five years past diagnosis,...
As you snack on turkey sandwiches and leftover pumpkin pie, check out the articles highlighted by the editors of...
Once considered undruggable, mutant KRAS has emerged in recent years as a viable target for anticancer therapeutics. As a...
One year, to the day, after winning the Nobel Prize in Chemistry for her groundbreaking work on the genetic...
Each month, the editors of the nine AACR journals select one article from each issue to highlight. The featured articles for September described the preclinical evaluation...